Evaxion Unveils Novel AI-Discovered Antigens Showing Protective Effects in CMV Vaccine Program
Evaxion A/S has announced positive preclinical results for its CMV vaccine program, EVX-V1, using its AI-Immunology™ platform. The AI-discovered antigens have shown the ability to induce immune responses and inhibit viral infection. The vaccine candidate includes a proprietary pre-fusion glycoprotein B antigen with superior CMV neutralization. Preclinical development continues with further antigen optimization.
Evaxion A/S, a clinical-stage TechBio company, has announced positive preclinical data for its novel cytomegalovirus (CMV) vaccine program, EVX-V1. Using its proprietary AI-Immunology™ platform, Evaxion has identified entirely new CMV antigens that have demonstrated the ability to induce specific immune responses, inhibit viral infection, and reduce cell-to-cell spread in both cellular and animal models. The EVX-V1 vaccine candidate combines these AI-discovered antigens with AI-optimized versions of established vaccine targets, including a proprietary pre-fusion glycoprotein B (gB) antigen that has shown superior CMV neutralization compared to traditional gB antigens. Preclinical development is ongoing, with further antigen investigation and optimization underway. The company did not indicate whether these results have already been presented at a scientific meeting or will be presented in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
